Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by CancerSlayer


V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:New Data Format

enriquesuave wrote: CancerSlayer wrote: enriquesuave wrote: I would say...

April 27, 2023

V.TLT

RE:RE:RE:RE:RE:RE:New Data Format

enriquesuave wrote: I would say more around 45-55% durable CR as some of the...

April 27, 2023

V.TLT

RE:RE:RE:RE:New Data Format

enriquesuave wrote: Th KM curve includes the 12 undertreated patients as it...

April 27, 2023

V.TLT

RE:An Interesting Discussion

Johnandrose22 wrote: This morning I was speaking with one of my clients who...

April 27, 2023

V.TLT

RE:RE:RE:New Data Format

The reported data, plot & KM Curve "does"  include the 12...

April 27, 2023

V.TLT

RE:New Data Format

Eoganacht wrote: The new format for presenting data at first seemed a little...

April 27, 2023

V.TLT

RE:RE:RE:RE:So they STILL have not applied for BTD???

  Clarification of previous post highlighted below... My focus is...

April 27, 2023

V.TLT

RE:RE:RE:So they STILL have not applied for BTD???

enriquesuave wrote: Rumpl3StiltSkin wrote: They will probably apply for BTD...

April 27, 2023

V.TLT

RE:RE:Shout Out to TLD1433 PDT by Spanish Researchers

wildbird1 wrote: Eoganacht, Great article. What I love most about it, is a...

April 20, 2023

V.TLT

RE:RE:RE:RE:RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

N0taP00p wrote: Eoganacht, I was curious about the assumption that Theralase...

April 20, 2023

V.TLT

RE:Let the 450 day CR% numbers talk.

wildbird1 wrote: If you want to feel good about your investment in TLT...

April 16, 2023

V.TLT

RE:RE:RE:RE:Keytruda = $265,000 (17 doses per year)

N0taP00p wrote: Slayer, what are your thoughts on the smaller sample size...

April 14, 2023

V.TLT

RE:RE:RE:Keytruda = $265,000 (17 doses per year)

CancerSlayer wrote: DJDawg wrote: Hi I may be wrong but there is also the...

April 13, 2023

V.TLT

RE:RE:Posts

Unlike many others in the medical/oncology R&D field, the FDA did award...

April 13, 2023

V.TLT

RE:RE:Keytruda = $265,000 (17 doses per year)

DJDawg wrote: Hi I may be wrong but there is also the maint protocol for the...

April 13, 2023

V.TLT

RE:RE:RE:AUA Poster Session

Here you go... https://theralase.com/wp-content/uploads/2023/02/2023-GU...

April 11, 2023

V.TLT

RE:RE:RE:News please...

Eoganacht wrote: Right. Theralase shareholder - potential Moneybags or...

April 11, 2023

V.TLT

RE:RE:RE:MY TAKE

Good points...the only thing that matters to me is the near-term protection...

April 6, 2023

V.TLT

RE:RE:RE:RE:RE:Example of a jv deal

N0taP00p wrote: Well said, Slayer. I do agree with Eoganacht's point...

April 4, 2023

V.TLT

RE:RE:RE:Example of a jv deal

Eoganacht wrote: Conferences are more about educating urologists as to the...

April 4, 2023